The COVID-19 pandemic catalyzed a rapid and necessary transformation in the delivery of healthcare services, especially for vulnerable populations with opioid use disorder (OUD). Regulatory flexibilities introduced during the early months of the pandemic permitted telehealth-based initiation and maintenance of buprenorphine treatment without the requirement for an in-person visit. These changes created a unique natural […]
